GlassScriptPhysician profile
Julie Larue
NPI 1063936508
$2,711.63
in general payments reported to CMS, 2019-2025
20 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $427 · 2023: $360 · 2024: $569 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $571.41 | 2021-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $227.55 | 2021-2024 | Airsupra |
| Axsome Therapeutics, INC. | $195.27 | 2025 | Auvelity |
| Zoll Respicardia, INC. | $151.53 | 2021 | |
| Boston Scientific Corporation | $130.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $126.20 | 2024 | Voquezna |
| Abbott Laboratories | $125.07 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $123.98 | 2025 | Lumryz |
| Genzyme Corporation | $122.92 | 2021 | |
| Glaxosmithkline, LLC. | $122.09 | 2024 | Arexvy |
| Biohaven Pharmaceuticals, INC. | $120.44 | 2021 | |
| Exact Sciences Corporation | $105.90 | 2023 | Cologuard Collection Kit |
| Opko Pharmaceuticals, LLC | $104.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.04 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $77.57 | 2023 | Valtoco |
| Cequr Corporation | $71.86 | 2025 | Cequr Simplicity |
| Paratek Pharmaceuticals, INC. | $62.99 | 2024 | Nuzyra |
| Scpharmaceuticals INC. | $51.39 | 2023 | |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Larue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.